06 August 2019

Minicare: Big Mistake Opens Door For Siemens

By CM Life Science

Last week I posted about Siemens Healthineers’ acquisition of Minicare and it received an incredible reaction.

It’s not surprising really. This deal has it all: a market leader, an exciting product and plenty of controversy.

So, what does it all mean?

First off, I should point out that the Minicare I-20 could be a market leading product with its handheld point-of-care (PoC) system able to exclude or confirm the presence of suspected heart attacks. It’s a product that has so much potential, when in the right hands.

Although Siemens Healthineers’ already has quite a strong PoC system, ’epoc’, this will be a welcome addition and make the company a real force in the PoC space.

Siemens Healthineers’ backing of this technology does not spell good news for competitors like Abbott (iStat) and Quidel (Triage), who now must invest and innovate to remain competitive in the market.

Philips Healthcare won’t be enthused by the news either. Having invested a decade’s worth of research on Minicare’s technology, originally under the name of Magnotech, before parting ways last year because of ‘inadequate business opportunities.’ This lack of faith could prove to be a huge mistake.

Over the last year, Minicare claims to have improved its device even more, reaching a new level of sensitivity and accuracy. If this is true, the device will be able to produce similar levels of performance to heavy-weight hospital equipment with the advantage of being handheld and mobile.

With a new home, the Minicare I-20 will cement its place as the market leader. As always, this extra competition will encourage innovation among competitors. This means that we can look forward to the emergence of exciting new products and improved healthcare in the future.

Share
Back to the top
By CM Life Science

Recommended.

Connecting Lateral Flow to the 21st Century.
02 April 2020 By Nathan Rigby

Connecting Lateral Flow to the 21st Century.

To find out more about Bond Health, I spoke to Phil Groom, Commercial Director, and Viktoriya Agova, Marketing Manager from Bond Health to hear how they're connecting the world of lateral flow.

Molecular Diagnostics' Finest Hour.
26 March 2020 By Nathan Rigby

Molecular Diagnostics' Finest Hour.

COVID-19 is one of the biggest challenges healthcare has ever faced. Crucial work is being done throughout molecular diagnostics to limit the spread in what many would call the space's finest hour.

Are Decentralised Trials Healthcare's Gateway to the Future?
17 January 2020 By Matthew Barrows

Are Decentralised Trials Healthcare's Gateway to the Future?

Decentralised, virtual, home, remoteā€¦ whatever the name of this type of trial, it's widely agreed they will be crucial to advancing healthcare.

We Will Beat Cervical Cancer.
09 January 2020 By Eleanor Doolin

We Will Beat Cervical Cancer.

While it remains the fourth most common type of cancer for women worldwide, cervical cancer is one of the most preventable and curable with early diagnosis. Let's raise awareness and get more women around the world screened.

Get the latest into your inbox.